Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.
Clin Infect Dis. 2019 Apr 08;68(Supplement_3):S200-S205
Authors: Shortridge D, Flamm RK
Bacterial skin infections result in significant morbidity and have contributed to enhanced health-care resource utilization. The problem is heightened by emerging antimicrobial resistance. Multiple novel agents active against resistant pathogens that cause skin infections-including dalbavancin, tedizolid phosphate, oritavancin, and delafloxacin-have been approved over the past 5 years. Common features of these agents include gram-positive activity and favorable safety. Of these agents, delafloxacin is unique in being active against both gram-positive and gram-negative pathogens that cause skin infections, including those resistant to other antimicrobial agents. It is, therefore, an effective option for the treatment of skin infections.
PMID: 30957168 [PubMed - in process]